Wave Life Sciences 配当と自社株買い
配当金 基準チェック /06
Wave Life Sciences配当金を支払った記録がありません。
主要情報
n/a
配当利回り
-35.8%
バイバック利回り
| 総株主利回り | -35.8% |
| 将来の配当利回り | 0% |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
ナラティブの更新 • May 23
WVE: Obesity Program Data And RNA Editing Validation Will Drive Future Upside
Wave Life Sciences' analyst price target has been revised lower from $49.99 to $40.15 as analysts factor in mixed readouts for WVE-006 and WVE-007, tougher competition from peers, and updated probabilities of success, although some firms still see room for upside based on recent pipeline data. Analyst Commentary Recent Street research on Wave Life Sciences reflects a split view, with some firms cutting targets after recent data updates and others highlighting what they see as attractive upside if the company executes on its current programs.Seeking Alpha • May 20
Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data
Summary Wave Life Sciences Ltd. retains a Strong Buy rating, driven by near-term Accelerated Approval catalysts for WVE-N531 and WVE-006. The company is on track to file an NDA for WVE-N531 in DMD exon 53 skipping in 2026, targeting approval based on dystrophin production and functional testing. Recent phase 1b/2a data for WVE-006 in AATD showed up to 70.5% Z-AAT reduction with multi-dosing, with key FDA feedback and 600 mg multi-dose data expected in mid/late 2026. WVE's robust $544.6M cash balance funds operations into Q3 2028, supporting continued pipeline advancement and multiple potential inflection points. Read the full article on Seeking Alpha
ナラティブの更新 • May 04
WVE: Obesity Data And 2026 Catalysts Will Shape Future Upside
Analysts have reduced their price targets on Wave Life Sciences, driving an internal fair value estimate from about $34.06 to $22.19 as they factor in updated revenue growth, margin expectations, and pipeline competitiveness against GLP-1 treatments. Analyst Commentary Recent research coverage on Wave Life Sciences has become more mixed, with a cluster of price target cuts around updated obesity data and GLP-1 competition, alongside a smaller group of firms that remain constructive on the pipeline and long term opportunity.ナラティブの更新 • Apr 19
WVE: Obesity And AATD Pipeline Progress Will Drive Future Upside
Analysts have reduced the average price target for Wave Life Sciences by about $1, reflecting a mix of lower Street targets after recent obesity and GLP-1 competitiveness concerns, partly offset by a few upward revisions following pipeline updates. Analyst Commentary Recent Street commentary around Wave Life Sciences has been mixed, with several firms cutting price targets and questioning the competitiveness of the obesity and GLP 1 pipeline, while a smaller group of bullish analysts has highlighted potential upside tied to clinical catalysts and management execution.ナラティブの更新 • Apr 05
WVE: Obesity Pipeline Data And Regulatory Pathways Will Drive Future Upside
Analysts have adjusted the fair value estimate for Wave Life Sciences to $50.75 from $45.17, reflecting updated views on its obesity and AATD pipeline opportunities, as well as a mix of recent price target revisions across the Street. Analyst Commentary Recent research on Wave Life Sciences shows a split tape, with some firms turning more cautious while others highlight potential value in the obesity and AATD programs.ナラティブの更新 • Mar 22
WVE: Obesity Data And 2026 AATD Milestones Will Drive Future Upside
Analysts have nudged the fair value estimate for Wave Life Sciences to $34.06 from $33.50, reflecting updated views on its obesity and AATD pipeline progress and higher future P/E assumptions informed by recent price target revisions across the Street. Analyst Commentary Street research on Wave Life Sciences is centering on the obesity and AATD programs, with several firms updating their targets and models after recent management meetings and clinical readouts.ナラティブの更新 • Mar 07
WVE: Obesity Fat Reduction Data Will Drive Future Upside Potential
Analysts have inched their fair value estimate for Wave Life Sciences higher from $33.38 to $33.50. This reflects updated views on WVE-007's obesity program and potential regulatory pathways, as well as the recent cluster of higher Street price targets that highlight upcoming data as a key near term catalyst.ナラティブの更新 • Feb 20
WVE: INHBE Cardiometabolic Data And AATD Rights Will Drive Future Upside
Analysts have nudged their fair value estimate for Wave Life Sciences higher, with the updated target moving from about $33.06 to $33.38 as they factor in recent bullish coverage, higher Street price targets, and evolving views on revenue growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts have recently highlighted Wave Life Sciences as a name to watch, with several research shops updating their views and price targets in quick succession.ナラティブの更新 • Feb 06
WVE: INHBE Fat Reduction And AATD Progress Will Drive Future Upside
Analysts increased their price target on Wave Life Sciences by about $1 to roughly $33 per share, as recent bullish coverage and supportive data for its INHBE-targeting approach and AATD program reinforced confidence in the company's long term potential. This was viewed as justification for a higher fair value estimate despite a slightly higher discount rate and modestly adjusted growth and margin assumptions.ナラティブの更新 • Jan 22
WVE: Obesity And RNA Editing Progress Will Drive Future Upside Potential
Analysts have lifted their price targets on Wave Life Sciences, with our fair value estimate moving from US$32.60 to about US$45.17. This reflects growing confidence in its INHBE-targeting obesity program, validation of its RNA editing approach versus competitors, and supportive commentary around its Huntington’s disease and weight loss pipelines.ナラティブの更新 • Jan 08
WVE: INHBE Obesity Program Will Drive Future Upside Potential
Analysts have inched up their fair value estimate for Wave Life Sciences to about $31.93 per share from $31.60. This reflects updated views on the company’s INHBE-targeting obesity program, strengthened competitive position in AATD, and continued interest in its broader genetic medicines pipeline.ナラティブの更新 • Dec 24
WVE: Obesity RNA Editing Advances Are Expected To Drive Future Upside
Analysts have lifted their fair value estimate for Wave Life Sciences to approximately $31.60 per share from about $27.21, citing strengthened competitive positioning in genetic medicines, positive obesity pipeline data, and limited negative read-throughs from peer setbacks as key drivers. Analyst Commentary Bullish analysts highlight that recent competitive developments in alpha-1 antitrypsin deficiency have effectively de-risked Wave Life Sciences' editing approach, supporting higher confidence in long term market share and cash flow potential.分析記事 • Dec 16
Subdued Growth No Barrier To Wave Life Sciences Ltd. (NASDAQ:WVE) With Shares Advancing 128%
The Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has done very well over the last month, posting an excellent...ナラティブの更新 • Dec 10
WVE: Obesity RNA Editing Breakthrough Is Expected To Drive Future Upside
Analysts have raised their price target on Wave Life Sciences by about $7 per share, reflecting increased confidence in the companys validated RNA editing approach, its expanding obesity pipeline, and its insulated Huntington's disease program despite sector specific setbacks. Analyst Commentary Bullish analysts view recent sector developments as reinforcing Wave Life Sciences competitive positioning, particularly in RNA editing and obesity, and see room for further upside as the company executes on its clinical milestones.分析記事 • Nov 01
Wave Life Sciences Ltd. (NASDAQ:WVE) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have had a really impressive month, gaining 29% after a shaky period...分析記事 • Sep 14
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have retraced a considerable 29% in the last month, reversing a fair...分析記事 • Aug 04
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Trimmed Their Revenue Forecasts By 13%
One thing we could say about the analysts on Wave Life Sciences Ltd. ( NASDAQ:WVE ) - they aren't optimistic, having...分析記事 • Jul 31
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 26% Share Price Surge Not Quite Adding Up
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders would be excited to see that the share price has had a great month...分析記事 • Jul 07
We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Jun 01
Risks Still Elevated At These Prices As Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Dive 26%
Unfortunately for some shareholders, the Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has dived 26% in the last...分析記事 • Apr 04
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 41% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Unfortunately for some shareholders, the Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has dived 41% in the last...Seeking Alpha • Mar 27
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531
Summary Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved in the phase 2 FORWARD-53 study, using WVE-N531 for the treatment of patients with DMD amenable to exon 53 skipping; an average dystrophin expression of 7.8% was achieved. The Duchenne Muscular Dystrophy market, in the 7 major markets, will reach $5.2 billion by 2033. Positive FDA meeting held; potential for WVE to file for Accelerated Approval of WVE-N531 for DMD patients amenable to Exon 53 skipping in 2026. Read the full article on Seeking Alpha
新しいナラティブ • Mar 23
WVE-007 And WVE-006 Will Offer New Treatment Options For Obesity And AATD
Advancing innovative treatments like WVE-007 and WVE-006 could drive revenue growth by addressing current therapy limitations and capturing market share in obesity and AATD.Seeking Alpha • Jan 08
Wave Life Sciences Is A Buy On Pipeline Prospects
Summary Wave Life Sciences develops stereopure oligonucleotides targeting genetic mutations, with lead assets in DMD, AATD, and Huntington's Disease showing promising data. Major collaborations with GSK and positive trial results have significantly boosted WVE's stock, despite previous flat performance and management missteps. Financially strong with $525M in cash, the Company has a solid runway for 8–10 quarters, though approval for its programs is still years away. Despite valuation risks, WVE's successful data, collaborations, and large target markets make it a buy; start small, accumulate at dips, and hold long term. Read the full article on Seeking Alpha分析記事 • Nov 15
US$22.20 - That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results
Wave Life Sciences Ltd. ( NASDAQ:WVE ) missed earnings with its latest quarterly results, disappointing...分析記事 • Nov 09
Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking
Despite an already strong run, Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have been powering on, with a gain of 95...Seeking Alpha • Oct 16
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Summary Wave Life Sciences announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of alpha-1 antitrypsin deficiency patients. A single subcutaneous administration of 200 mg of WVE-006 resulted in the presence of wild-type alpha-1 antitrypsin protein; This led to a more than 60% increase of AAT. The global Alpha-1 Antitrypsin Deficiency market is expected to reach a $10 billion market value by 2033. Additional results from the phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of patients with alpha-1 Antitrypsin Deficiency, expected in 2025. Read the full article on Seeking Alpha分析記事 • Sep 25
There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump
Despite an already strong run, Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have been powering on, with a gain of 43...Seeking Alpha • Sep 24
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Summary Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531, showing >5% dystrophin production. The safety profile of WVE-N531 is strong, but competition from gene therapies and the need for further efficacy data present significant challenges. Investors should consider waiting for 48-week data and clearer regulatory paths before committing, despite WVE stock's current upside potential. Despite past setbacks, Wave's innovative RNA-targeting technology and strategic partnerships, like with GSK, position it for potential breakthroughs in multiple disease areas. A successfully approved DMD candidate could ultimately turn Wave into a double-digit billion company, like rival Sarepta Therapeutics, but that eventuality remains a long way off. Read the full article on Seeking Alpha分析記事 • Sep 08
Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher
Shareholders in Wave Life Sciences Ltd. ( NASDAQ:WVE ) may be thrilled to learn that the analysts have just delivered a...分析記事 • Aug 05
We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Jun 25
Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now
You may think that with a price-to-sales (or "P/S") ratio of 5.7x Wave Life Sciences Ltd. ( NASDAQ:WVE ) is a stock to...分析記事 • Apr 09
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Mar 09
Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Summary Wave Life Sciences is entering the obesity market, selecting INHBE as a clinical candidate. The company faces intense competition from other RNA-based therapeutics companies, such as Alnylam, that have successfully brought treatments to market. Investment recommendation: Hold, due to intense competition, financial sustainability concerns, and current market sentiment. Read the full article on Seeking Alpha分析記事 • Mar 03
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders are no doubt pleased to see that the share price has bounced 30% in...分析記事 • Sep 13
We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • May 08
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on Wave Life Sciences Ltd. ( NASDAQ:WVE ) - they aren't optimistic, having...決済の安定と成長
配当データの取得
安定した配当: WVEの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: WVEの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Wave Life Sciences 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (WVE) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.2% |
| 業界平均 (Pharmaceuticals) | 2.1% |
| アナリスト予想 (WVE) (最長3年) | 0% |
注目すべき配当: WVEは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: WVEは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: WVEの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: WVEが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/25 00:56 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Wave Life Sciences Ltd. 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。29
| アナリスト | 機関 |
|---|---|
| Alec Stranahan | BofA Global Research |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Whitney Ijem | Canaccord Genuity |